Chikungunya AG129 Mouse Model

Chikungunya virus (CHIKV) is a mosquito-borne alphavirus endemic in Africa and Asia that causes a debilitating disease in over 2 million people every year in explosive outbreaks. Currently there are no vaccines or therapeutics available for this emerging virus. IBT Bioservices has established a lethal model for this disease based on previous publication (Partidos, 2011).

This model utilizes AG129 mice deficient in IFN α/β and IFN γ signaling and an attenuated strain of CHIKV (181/25). It is an ideal model for testing drug and vaccine candidates and has the following advantages:

  • Lethal challenge dose established allowing efficacy testing using morbidity and mortality endpoints.
  • Virus causes necrotic histopathological changes in the spleens of infected mice.
  • Utilizes an attenuated strain (CHIKV 181/25) that is safe to handle in BSL-2 environment thereby avoiding high costs of BSL-3 studies.
  • Successfully used to demonstrate efficacy of CHIKV experimental vaccine candidates.
  • Adoptive transfer of hyperimmune serum protects against lethal challenge suggesting the utility of the model to evaluate therapeutic candidates.


IBT Bioservices continues to conduct critical work as an essential business under the State of Maryland’s COVID-19 response directive. We have implemented a risk management plan and are continually monitoring the situation to ensure continuation of research according to public health services recommended best-practices for keeping our employees and the community safe. 

The IBT Bioservices team will continue to deliver high quality products and services for every project. If you have any questions contact us at